人工胰腺 z-bo 2020-09-21 401

　　Recently, Debiotech, a subsidiary of Swiss medical technology company, has cooperated with two research centers in Switzerland to jointly develop a new generation of artificial pancreas suitable for diabetic patients. The researchers' goal is to improve the automatic insulin delivery device by using a microelectromechanical system to control the insulin pump. They use an algorithm to measure the patient's blood glucose level, the patient's time, and assess the patient's needs based on the expected activity of adjusting the infusion rate of the insulin pump. The obstacle to long-term production of artificial pancreas is to generate sufficiently accurate blood glucose data and analyze the relevant data to automatically inject insulin. Current continuous glucose monitoring insulin pump combinations on the market (such as Medtronic's MiniMed) require users to determine their insulin. In addition, all dynamic blood glucose monitoring systems (CGM) need to be calibrated daily, so the plan is to eliminate the benefits of this equipment. The artificial pancreas can accurately and automatically input appropriate levels of hormones (such as insulin), making it easier for diabetic patients to control their blood sugar levels within a specified range, and is currently undergoing research and development. I'm going out. There are many methods, but none of them meets market requirements. Peter Diem, head of the Department of Endocrinology at the University Hospital of Bern, said that patients with diabetes must now follow basic treatment methods, such as blood glucose measurement, dose calculation, and insulin injection. The concept in this article is to create a single system that can help guide these operations without intervention. .

　　The system includes JewelPump, Debiotech's MEMS integration, disposable device chip technology, and a small drainage patch pump that can dispense 500U of insulin for 7 days or more. The device integrates a blood glucose monitoring reader and a small device application including a microcomputer. This new artificial pancreas algorithm can also run on wireless PDA devices.

　　Earlier this year, Deviotech licensed continuous blood glucose monitoring technology. Finally, the researcher Stavroula Mougiakakou uses our proposed algorithm for patients. The algorithm is very easy to use and introduces real-time personalized changes based on enhanced learning. Changes in the body can compensate for the impact of uncertain events.